Nature Biotechnology 24, 403 - 410 (2006)
doi:10.1038/nbt0406-403
Putting pharmacogenetics into practiceMichael M Hopkins1, Dolores Ibarreta2, Sibylle Gaisser3, Christien M Enzing4, Jim Ryan5, Paul A Martin6, Graham Lewis7, Symone Detmar4, M Elske van den Akker-van Marle4, Adam M Hedgecoe8, Paul Nightingale1, Marieke Dreiling3, K Juliane Hartig3, Wieneke Vullings4
& Tony Forde51
SPRU: Science and Technology Policy Research, The Freeman Centre, University of Sussex, Brighton BN1 9QE, UK. m.m.hopkins@sussex.ac.uk
2
European Commission Joint Research Center, Institute for Prospective Technological Studies, Edificio Expo, Inca Garcilaso, E-41092 Seville, Spain. 3
Fraunhofer Institute Systems and Innovation Research, 48 Breslauer Str. 76139 Karlsruhe, Germany. 4
TNO: Netherlands Organization for Applied Scientific Research, Innovation Policy Group, 97 Schoenmakerstraat, PO Box 6030, 2600 JA Delft, The Netherlands. 5
The CIRCA Group Europe Limite, 26 Upper Pembroke St., Dublin 2, Ireland. 6
Institute for the Study of Genetics, Biorisks and Society, University of Nottingham, Nottingham, NG7 2RD UK. 7
Science and Technology Studies Unit, University of York, York YO10 5DD UK. 8
Department of Sociology, University of Sussex, BN1 9SN UK. Genetics is slowly explaining variations in drug response, but applying this knowledge depends on implementation of a host of policies that provide long-term support to the field, from translational research and regulation to professional education.
|
